CCL2 and chronic kidney disease: By demonstrating an Empa-mediated inhibition of basal and IL-1β-induced MCP-1/CCL2 as well as ET-1 expression in two independent HPTC lines under normoglycemic conditions, we present novel evidence for anti-inflammatory effects of SGLT2i that might account for SGLT2i-mediated renoprotection in CKD.